Compare Futu Holdings Ltd (FUTU) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Gilead Sciences, Inc. — how do they compare? Futu Holdings Ltd trades at $110.07 (market cap $15.25B), while Gilead Sciences, Inc. trades at $147 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 12× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Gilead Sciences, Inc. for 111 Days on average.
| FUTU | GILD | |
|---|---|---|
Market Cap | $15.25B | $182.40B |
Volume | 812,567 | 4,469,821 |
Sector | Financials | Health |
52-Week High | $199.04 | $155.80 |
52-Week Low | $89.76 | $116.74 |
Typical Hold Time | 34 Days | 111 Days |
Enterprise Value | $15.59B | $205.46B |
Dividend Yield | 2.39% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $109.68, down 3.12% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $22.85B in 2025 with a net income margin of 49.62%, while valuation ratios like a P/E of 10.95 suggest potential undervaluation. Recent news includes Moomoo's partnership with X and a class action lawsuit deadline, adding mixed sentiment.
The outlook is cautiously optimistic due to robust earnings growth and analyst upside targets near 33%, but risks from legal issues and competitive pressures warrant monitoring. Investors may find value if the company executes on overseas expansion, though volatility from technical bearishness persists.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
